NUKEMED, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.spectronrx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Early Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (100.0%)Safety and Targeting of Anti-hk2 Antibody in mCRPC
Early Phase 1
Terminated
- Conditions
- Castration-Resistant Prostatic CancerMetastatic Disease
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- SpectronRX
- Target Recruit Count
- 27
- Registration Number
- NCT04116164
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
News
Clarity Pharmaceuticals Secures Major Manufacturing Deal to Scale Cu-SAR-bisPSMA Production for Prostate Cancer Diagnostics
Clarity Pharmaceuticals has entered a five-year commercial manufacturing agreement with SpectronRx to produce up to 400,000 patient-ready doses of Cu-SAR-bisPSMA annually for prostate cancer diagnosis and treatment.
Clarity Pharmaceuticals and SpectronRx Partner for Phase III Trial Manufacturing of Cu-64 SAR-bisPSMA
Clarity Pharmaceuticals partners with SpectronRx for manufacturing Cu-64 SAR-bisPSMA, ensuring reliable supply for Phase III trials.